NCT07795164Phase 3Recruiting

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

Study sponsor: Altimmune, Inc. · ALT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-12Estimated
Enrollment · participants1800Estimated
Source updated2026-11-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.